Topic: nonalcoholic steatohepatitis (NASH)
Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis, to the tune of $225 million.
Fractyl presented new data from two trials of its intestine-resurfacing procedure, including demonstrated improvements in Type 2 diabetes.
What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.
Durect's treatment lowered scores that reflect the likelihood a person with alcoholic hepatitis will die within a certain period of time.
Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.
The deal gives Novo control of UD-014, a small-molecule inhibitor of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1.
Gilead Sciences has tapped FierceMedTech Fierce 15 winner Glympse Bio to help develop a non-invasive diagnostic test for nonalcoholic steatohepatitis.
4. John McHutchison, Gilead Sciences
The NASH drug, PLN-1474, is a small molecule inhibitor of integrin αVβ Pliant thinks can reduce the growth of fibrotic tissue in the liver.
Scientists have long known that fatty livers can significantly increase the risk of the organ developing cancer. Now, early research shows why.